Havrix Adulto

Havrix Adulto is a hepatitis A vaccine containing algeldrate and inactivated hepatitis A virus antigen, supplied as an injectable solution for intramuscular use. It is a prescription‑only product marketed in the European Union. The vaccine is formulated to induce active immunity against hepatitis A virus by stimulating protective antibodies. Strength and dosage form are standardized per EU regulatory specifications, according to current guidelines and practice.

Havrix Adulto is indicated for the prevention of hepatitis A infection in adults and adolescents who have not been previously immunized. - Primary prophylaxis for travelers to regions where hepatitis A is endemic. - Post‑exposure prophylaxis for individuals with recent contact with hepatitis A cases. - Immunization of people at occupational risk, such as laboratory workers handling hepatitis A specimens. - Vaccination of individuals with chronic liver disease to reduce severe outcomes. - Use in outbreak settings to quickly increase community immunity. - Administration as part of combined hepatitis A and B vaccination schedules when appropriate.

The safety profile of Havrix Adulto reflects the typical reactions observed with inactivated viral vaccines.

Common: - Mild pain, redness, or swelling at the injection site. - Low‑grade fever lasting less than 24 hours. - Headache or fatigue that resolves spontaneously. - Transient muscle aches or joint discomfort. - Nausea or mild gastrointestinal upset. - Dizziness or feeling of light‑headedness. - Localized itching or rash at the injection site. - Mild swelling of lymph nodes near the injection site. - Temporary feeling of warmth or tingling at the injection area.

Serious: - Severe allergic reaction (anaphylaxis) with difficulty breathing or swelling of the face. - Neurological events such as Guillain‑Barré syndrome, though extremely rare. - Autoimmune phenomena such as thrombocytopenia, reported very rarely.

Before administering Havrix Adulto, healthcare providers should consider several precautionary factors to ensure safe and effective immunization. - Verify that the patient has no known severe allergy to any vaccine component, especially gelatin or aluminum salts. - Defer vaccination in individuals with acute moderate or severe illness until recovery. - Assess pregnancy status; vaccination may be postponed if the risk is unclear. - Review history of immune system disorders, as response to the vaccine may be reduced. - Ensure proper intramuscular injection technique to minimize local reactions. - Document previous hepatitis A vaccination to avoid unnecessary repeat dosing.

Havrix Adulto generally has a low potential for drug interactions, but certain concomitant therapies may require attention.

Avoid: - Concurrent administration with other live viral vaccines is not recommended; separate them by at least 4 weeks. - Use with immunoglobulin products intended for hepatitis A prophylaxis may diminish vaccine efficacy.

Use with caution: - Patients receiving immunosuppressive therapy may have a reduced antibody response; consider post‑vaccination serology. - Anticoagulant therapy (e.g., warfarin) may increase the risk of injection‑site bruising; apply pressure after injection. - Chronic liver disease patients should be monitored for any unexpected hepatic changes after vaccination. - If the patient is receiving antipyretic medication, it can be given to alleviate mild fever without affecting immunogenicity.